![shutterstock_2658171737 [Converted]_Smaller.jpg](https://static.wixstatic.com/media/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg/v1/fill/w_980,h_327,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg)
Member Spotlight
Dana M. Adams, PA-C, MS, ATC
Dana M. Adams, PA-C, MS, ATC, is a physician assistant with a background in sports medicine, athletic training, orthopedics, and chronic pain management. At Blue Ridge Pain Management, she specializes in caring for patients with chronic pain, with a particular focus on cancer pain and intrathecal pump therapies. Dana works closely with oncology, neurosurgery, and interventional radiology teams to improve the quality of life for patients with cancer and has shared her expertise through professional education programs. She is also an active member of the Virginia Pain Society and serves as co-chair for its 2027 annual meeting.
INDUSTRY NEWS
Will recent FDA approval of a novel
nonopioid analgesic be a game changer?
Physician's Weekly
The Food and Drug Administration recently approved Journavx, a first-in-class oral, nonopioid, highly selective sodium channel blocker indicated as a treatment for adults with moderate to severe acute pain. Clinical data revealed that this agent is an effective, well-tolerated medicine without evidence of addictive potential, indicated for use with all types of moderate to sever acute pain.
